| 摘要: |
| 肝细胞癌(hepatocellular carcinoma,HCC)是全球范围内高发性恶性肿瘤之一,目前对于肝癌的临床治疗非常的有限。仅有的一线治疗药物索拉菲尼(Sorafenib)和乐伐替尼(Lenvatinib)也未能显著的延长患者生存期。因此,寻找新的治疗靶点尤为迫切。大量数据表明,缺氧是实体瘤的一个重要特征,在缺氧条件下,肿瘤启动一系列的诱导因子来适应这种环境,缺氧诱导因子(hypoxia inducible factors,HIFs)就是其中起到核心调控作用的蛋白之一。已有研究报道,缺氧诱导因子参与肝细胞癌的发生发展,与临床预后存在显著相关性,因此以缺氧诱导因子为靶点来研发治疗药物成为研究热点。本文对缺氧诱导因子家族中主要成员缺氧诱导因子-1α与缺氧诱导因子-2α在肝细胞癌的作用进行简要综述,为肝细胞癌领域的研究和治疗提供新思路。 |
| 关键词: 缺氧诱导因子-1 缺氧诱导因子-2 肝细胞癌 |
| DOI:10.13506/j.cnki.jpr.2021.03.009 |
| 基金项目:国家青年科学基金项目(No.81703561) |
|
|
|
| Research progress of hypoxia-inducible factor-1/2 in hepatocellular carcinoma |
| GUO Haixin,HU Weiwei,YANG Yong,CHEN Zhen |
| (China Pharmaceutical University,Nanjing 210009,China) |
| Abstract: |
| Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world with high morbidity. At present, the clinical treatments of liver cancer are very limited. Although only Sorafenib and Lenvatinib are approved as first-line systemic treatments, which are available for advanced unresectable hepatocellular carcinoma, they still fail to provide a significant survival benefit to patients. Therefore, it is particularly urgent to find new therapeutic targets. A large number of studies indicated that hypoxia is an important feature of solid tumors, and under hypoxic conditions, tumors initiate a series of inducing factors to adapt to this environment. Hypoxia inducible factors (HIFs) family is one of the inducing factors that plays a core regulatory role. It has been reported that HIFs were involved in the occurrence and development of hepatocellular carcinoma, and there is a significant correlation with clinical prognosis. Therefore, the development of therapeutic targets based on HIFs has become a key spot in HCC therapy. This article briefly reviewed the role of HIF-1α and HIF-2α , two major members of the HIFs family, in hepatocellular carcinoma, and provides new strategies for the research and treatment of HCC. |
| Key words: HIF-1 HIF-2 HCC |